论文部分内容阅读
目的探讨肿瘤标志物联合检测在肝细胞癌诊断中的临床意义。方法应用酶联免疫吸附法（ＥＬＩＳＡ），参考Ｔｒｏｏｓｔ法和分光光度法分别对３０例肝细胞癌患者、３０例肝硬化患者及３０例正常人（对照组），进行血清甲胎蛋白（ＡＦＰ）、α－Ｌ－岩藻糖苷酶（ＡＦＵ）和唾液酸（ＳＡ）测定。结果肝癌患者上述各项肿瘤标志物水平均明显高于肝硬化组和对照组（Ｐ＜０．０１），肝癌患者血清中ＡＦＰ、ＡＦＵ和ＳＡ的阳性率分别为７０．０％，７６．２％和７０．０％。将上述３项肿瘤标志物进行联合检测，以任２项阳性为诊断标准，则联合检测对肝癌诊断的敏感性为８６．７％，特异性为９８．３％，准确性为９４．４％，阳性预示值为９３．７％，阴性预示值为９６．３％。结论血清ＡＦＰ、ＡＦＵ和ＳＡ联合检测对肝癌诊断具有实用价值。
Objective To explore the clinical significance of combined detection of tumor markers in the diagnosis of hepatocellular carcinoma. Methods Serum alpha-fetoprotein (AFP) was detected in 30 cases of hepatocellular carcinoma, 30 cases of cirrhosis and 30 controls (control group) by ELISA using Troost method and spectrophotometry. , α-L-fucosidase (AFU) and sialic acid (SA) assays. Results The above mentioned tumor markers were significantly higher in liver cancer patients than in liver cirrhosis group and control group (P<0.01). The positive rates of AFP, AFU and SA in liver cancer patients were 70.0% and 76.2 respectively. % and 70.0%. Combined detection of the above three tumor markers was performed, and if any of the 2 tumor markers were positive, the sensitivity of combined detection for the diagnosis of liver cancer was 86.7%, the specificity was 98.3%, and the accuracy was 94.4%. The positive predictive value was 93.7%, and the negative predictive value was 96.3%. Conclusion The combined detection of serum AFP, AFU and SA has practical value in the diagnosis of hepatocellular carcinoma.